
Atrial Fibrillation- Pipeline Insight, 2024
Description
Atrial Fibrillation- Pipeline Insight, 2024
DelveInsight’s, “Atrial Fibrillation- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Atrial Fibrillation: Overview
Atrial fibrillation (also called Afib or AF) is an irregular heart rhythm (arrhythmia) that begins in the upper (atria) of your heart. In atrial fibrillation, the normal cycle of electrical impulses in the heart is interrupted. This leads to a fast, chaotic heart rhythm and poor movement of blood from your atria to lower chambers (ventricles). There are three main types of atrial fibrillation.
- Paroxysmal Afib lasts less than one week and usually stops on its own without treatment.
- Persistent Afib lasts more than one week and needs treatment.
- Long-standing persistent Afib lasts more than a year and is sometimes difficult to treat.
The diagnosis of Afib includes physical examination and lab tests. Physical examination includes listening to your heart rhythm with a stethoscope, checking your pulse and blood pressure, checking the size of your thyroid gland to identify thyroid problems, looking for swelling in your feet or legs to identify heart failure, listening to your lungs to detect heart failure or infection and the tests include the following:
- Electrocardiogram (EKG or ECG): An EKG is usually the first test. It’s painless and takes about three minutes. It measures and records your heart’s electrical signals and allows your provider to see if your heart is beating normally.
- Echocardiogram (echo): An echo uses ultrasound technology to show heart movement. It can reveal problems with blood flow and heart muscle contractions.
- Blood tests: Sometimes, imbalances in our blood can cause Afib. Simple blood tests can show potassium and thyroid hormone levels and can help provider choose the best medicines based on your liver and kidney function.
Rate control medications to prevent the ventricles from beating too fast. Examples include digoxin, metoprolol, verapamil or diltiazem.
Rhythm control medications to help your heart beat in a normal sinus rhythm. Examples include procainamide, disopyramide, flecainide acetate, propafenone, sotalol, dofetilide or amiodarone.
Blood thinners (anticoagulant medications) to reduce the risk of blood clots and stroke. Examples include warfarin, warfarin alternatives or aspirin.
If medications don’t help your Afib, procedure or surgery is needed:
Electrical cardioversion electrically “resets” heart rhythm using low-energy shocks, but it may only be a temporary solution.
Pulmonary vein ablation uses catheters to deliver energy outside and around pulmonary veins. This procedure helps respond better to your Afib medications.
A permanent pacemaker may be inserted in case of slow heart rate. Usually, it’s only used if the patient have another arrhythmia in addition to Afib.
Left atrial appendage closure is a procedure that reduces your risk of blood clots and stroke.
The MAZE procedure creates scar tissue that helps heart’s electrical impulses travel in the right path. This procedure has a high success rate. If the patient have severe Afib symptoms and a history of stroke or blood clots, provider may recommend this option.
""Atrial Fibrillation- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.
This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atrial Fibrillation Emerging Drugs
- Abelacimab: Anthos Therapeutics, Inc.
- Etripamil: Milestone Pharmaceuticals
- GENCARO: ARCA biopharma
Further product details are provided in the report……..
Atrial Fibrillation: Therapeutic Assessment
This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Atrial Fibrillation
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Atrial Fibrillation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.
Atrial Fibrillation Report Insights
- Atrial Fibrillation Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atrial Fibrillation drugs?
- How many Atrial Fibrillation drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atrial Fibrillation and their status?
- What are the key designations that have been granted to the emerging drugs?
- ARCA biopharma Inc
- Anthos Therapeutics, Inc.
- Milestone Pharmaceuticals
- Armaron Biosciences
- Ono Pharmaceutical
- Hanmi Pharmaceutical
- HUYA Bioscience International
- Hyloris Pharmaceuticals
- Vivasc Therapeutics
- Espero BioPharma
- Gencaro
- Abelacimab
- Etripamil
- OMT 28
- NP 202
- HIP-2001
- Sulcardine
- HY-CVS-033
- CTP-amio
- ESP-001
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Atrial Fibrillation: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Atrial Fibrillation– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Abelacimab: Anthos Therapeutics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NP 202: Armaron Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Hip-2001: Hanmi Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Atrial Fibrillation Key Companies
- Atrial Fibrillation Key Products
- Atrial Fibrillation- Unmet Needs
- Atrial Fibrillation- Market Drivers and Barriers
- Atrial Fibrillation- Future Perspectives and Conclusion
- Atrial Fibrillation Analyst Views
- Atrial Fibrillation Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.